^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma
Published date:
11/04/2020
Excerpt:
We then performed a logistic regression to identify biomarkers with independent value to predict unsustained CR. Elevated LDH levels (HR: 2.9 [1.1 - 8.0], P =.038) and >20% PCs (HR: 2.8 [1.2 - 6.7], P =.020) at diagnosis together with persistent MRD (HR: 4.3 [1.9 - 9.6], P <.001) had independent value to predict unsustained CR in a multivariable analysis.
Secondary therapy:
dexamethasone
